UNSPSC 51262403: Amosulalol

This classification denotes an adrenergic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C69JI1BAU8. European Medicines Agency schedules Amosulalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Amosulalol generally arises in the molecular formula C18H24N2O5S.

UNSPSC 51262403 Amosulalol is a Commodity code that does not align with the state and local procurement activity currently tagged to it. The recent opportunity on record — Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems — involves emergency response and public health supplies, not amosulalol, a beta-blocker medication used in cardiovascular treatment. The code's nominal scope and the actual goods being procured under it show a significant mismatch, suggesting either a classification error in the source data or a sparse, misaligned activity pattern for this particular code in state and local markets.

Seminole County is the only issuing body with a recent documented opportunity under this code, posting an IFB on June 30, 2026 (with a due date listed as July 26, 2023, indicating a data inconsistency in the source). The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. No other states or jurisdictions appear in the available records for this code. Without additional opportunities reflecting genuine amosulalol procurement or pharmaceutical supply activity aligned to the code's stated name, this code presents limited decision-relevance for business development purposes at this time.